Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.
暂无分享,去创建一个
J. Sanderson | K. Woo | W. Chan | S. Chan | I. Shum | Y. Hung | K. Raymond
[1] R. Norris,et al. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). , 1995, The American journal of cardiology.
[2] K. Nakao,et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. , 1994, British heart journal.
[3] R. Lefkowitz,et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.
[4] A. Daul,et al. Positive inotropic effects of the beta 2-adrenoceptor agonist terbutaline in the human heart: effects of long-term beta 1-adrenoceptor antagonist treatment. , 1994, Journal of the American College of Cardiology.
[5] R. Doughty,et al. Beta-blockers in heart failure: promising or proved? , 1994, Journal of the American College of Cardiology.
[6] A R Jayaweera,et al. Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy? , 1993, Circulation.
[7] W. Edwards,et al. Natriuretic peptide system in human heart failure. , 1993, Circulation.
[8] P. Serruys,et al. Maximal blood flow velocity in severe coronary stenoses measured with a Doppler guidewire. Limitations for the application of the continuity equation in the assessment of stenosis severity. , 1993, The American journal of cardiology.
[9] A. Struthers,et al. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction , 1993, The Lancet.
[10] M. Brown,et al. Beta adrenoreceptor subtype cross regulation in the human heart. , 1993, British heart journal.
[11] M. Bristow. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. , 1993, The American journal of cardiology.
[12] H. Ikram,et al. Therapeutic controversies with use of beta-adrenoceptor blockade in heart failure. , 1993, The American journal of cardiology.
[13] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[14] A. Lenarda,et al. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy , 1991 .
[15] R. Candinas,et al. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. , 1990, Circulation.
[16] G. Mancia,et al. Sympathetic activation in congestive heart failure. , 1990, European heart journal.
[17] K Caidahl,et al. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.
[18] P. Erne,et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. , 1986, The New England journal of medicine.
[19] A. Mark,et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. , 1986, Circulation.
[20] M. Packer,et al. Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. , 1985, Circulation.
[21] J. Cohn,et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.
[22] E. Varnauskas,et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.
[23] S. Stephen. Unwanted effects of propranolol. , 1966, The American journal of cardiology.
[24] H. Burchell,et al. Focal myocarditis associated with pheochromocytoma. , 1966, The New England journal of medicine.
[25] R. Lefkowitz,et al. Enhanced Myocardial Function inTransgenic Mice Overexpressing theP2-Adrenergic Receptor , 1994 .
[26] Vincent T.F. Yeung,et al. Natriuretic Peptide Receptors , 1993 .
[27] I. Balažovjech,et al. The effect of short-term celiprolol therapy on platelet function in essential hypertension. , 1993, Cardiology.
[28] B. Prichard. β-blocking agents with vasodilating action , 1992 .
[29] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.